UBS Reiterates Neutral On Humana As Margin Visibility Remains Key Focus

UBS maintained its Neutral rating and $195 price target on Humana (NYSE: HUM), highlighting management’s emphasis on sustainable margins within its Medicare Advantage (MA) business.

During recent discussions, management underscored that long-term value calculations for MA members are contingent on achieving sustainable margin levels. The company indicated it would take corrective actions if the upcoming rate notice does not improve or if challenges arise within its new cohort of MA enrollees.

Regarding pricing for the 2026 book of business ahead of bid submissions in early June, management stated it expects greater clarity by April or May.

Humana also noted that projected 25% membership growth for 2026 could provide additional upside within its broader financial targets, though management prefers to assess trends through 2028 before drawing firm conclusions.

The company has implemented measures to enhance capital efficiency, including relocating its Wisconsin and Washington entities back to Kentucky, reducing capital requirements with support from reinsurance arrangements.